Skip to main content
OpenTrials
Completed

NCT Number: NCT03218566

Evaluating the Safety and Efficacy of the Indigo® Aspiration System in Acute Pulmonary Embolism

To determine the safety and efficacy of the Indigo Aspiration System for aspiration mechanical thrombectomy in patients with acute pulmonary embolism (PE)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Banner University Medical Center - Tucson, Tucson, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical signs and symptoms consistent with acute PE with duration of 14 days or less. Evidence of PE must be from CTA.
  • Systolic BP ≥ 90 mmHg with evidence of dilated RV with an RV/LV ratio > 0.9
  • Patient is 18 years of age or older

Exclusion criteria

  • tPA use within 14 days prior to baseline CTA
  • Systolic BP < 90mmHg for 15min or the requirement of inotropic support to maintain systolic BP ≥ 90 mmHg
  • Pulmonary hypertension with peak PA > 70 mmHg by right heart catheterization
  • History of severe or chronic pulmonary hypertension
  • Fi02 requirement > 40% or >6 LPM to keep oxygen saturations >90%
  • Hematocrit < 28%
  • Platelets < 100,000µL
  • Serum creatinine > 1.8 mg/dL
  • INR > 3
  • aPTT (or PTT) > 50 seconds on no anticoagulation
  • History of heparin-induced thrombocytopenia (HIT)
  • Contraindication to systemic or therapeutic doses of anticoagulants
  • Major trauma < 14 days
  • Presence of intracardiac lead
  • Cardiovascular or pulmonary surgery within last 7 days
  • Cancer requiring active chemotherapy
  • Known serious, uncontrolled sensitivity to radiographic agents
  • Life expectancy < 90 days
  • Female who is pregnant
  • Intracardiac Thrombus
  • Patients on ECMO
  • Current participation in another investigational study

Treatment and study plan

Indigo Aspiration System

Device

use of mechanical thrombectomy to treat pulmonary embolism

Primary outcomes

  1. Right Ventricle/Left Ventricle (RV:LV) Ratio

    Time frame: from baseline to 48 hours

    Change in RV/LV ratio per CTA

  2. Major Adverse Event Rate

    Time frame: within 48 hours

    A composite of: device-related death, major bleeding, device-related SAEs (a composite of clinical deterioration, pulmonary vascular injury, cardiac injury)

Secondary outcomes

  1. Device-related Death Rate

    Time frame: within 48 hours

  2. Major Bleeding Rate

    Time frame: within 48 hours

  3. Clinical Deterioration Rate

    Time frame: within 48 hours

  4. Pulmonary Vascular Injury Rate

    Time frame: within 48 hours

  5. Cardiac Injury Rate

    Time frame: within 48 hours

  6. Any-cause Mortality

    Time frame: within 30 days

  7. Device-related SAE Rate

    Time frame: within 30 days

  8. Symptomatic PE Recurrence Rate

    Time frame: within 30 days

Sponsors and collaborators

Lead sponsor

Penumbra Inc.

Industry

Registry information

Official study title

A Prospective, Multicenter Trial to Evaluate the Safety and Efficacy of the Indigo® Aspiration System in Acute Pulmonary Embolism

Acronym: EXTRACT-PE

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Jul 14, 2017
Registry last updated
Aug 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.